CD274 and cervical carcinoma: Pembrolizumab and nivolumab, PD-1/PD-L1 inhibitors, were included in the National Comprehensive Cancer Network guidelines as first-line treatments for PD-L1-positive advanced cervical cancer based on their clinical efficacy (9).